[28] Wang X, Zhou J, Doyle ME, Egan JM,2001. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kina...
然而,GLP-1受体激动剂类减肥药物在不良反应、停药后体重反弹等方面仍存在诸多待改进之处。为了应对这些问题,新一代减肥药物亟需引入新的药物作用机制(MOA,Mechanism of Action),以弥补GLP-1药物在减重适应症方面的不足。 在日益繁荣的减肥药物市场中,新产品需凭借显著优势脱颖而出,以实现有效竞争。制药企业已意识到...
然而,GLP-1受体激动剂类减肥药物在不良反应、停药后体重反弹等方面仍存在诸多待改进之处。为了应对这些问题,新一代减肥药物亟需引入新的药物作用机制(MOA,Mechanism of Action),以弥补GLP-1药物在减重适应症方面的不足。 在日益繁荣的减肥药物市场中,新产品需凭借显著优势脱颖而出,以实现有效竞争。制药企业已意识到...
[12] Gribble, F.M., Williams, L., Simpson, A.K., Reimann, F. 2003. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52:1147-1154. [13] ...
[28] Wang, X., Zhou, J., Doyle, M.E., Egan, J.M. 2001. Glucagon-like peptide-1 causes pancreatic duodenal homeobox-1 protein translocation from the cytoplasm to the nucleus of pancreatic beta-cells by a cyclic adenosine monophosphate/protein kinase A-dependent mechanism. Endocrinology 142:...
[12] Gribble, F.M., Williams, L., Simpson, A.K., Reimann, F. 2003. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52:1147-1154. [13] Sugiyama, K., Manaka, H., Kato, T., Yamatani, K., Tominaga, M., Sas...
[12] Gribble, F.M., Williams, L., Simpson, A.K., Reimann, F. 2003. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes 52:1147-1154. [13] Sugiyama, K., Manaka, H., Kato, T., Yamatani, K., Tominaga, M., Sas...
mechanism of actionsemaglutideWhat is known and objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are one of the preferred approved treatment options for people with type 2 diabetes (T2D) and inadequate glycaemic control. The objective of this review is to provide a general ...
[76] Trevaskis, J.L., Mack, C.M., Sun, C., Soares, C.J., D'Souza, L.J., Levy, O.E., et al. 2013. Improved glucose control and reduced body weight in rodents with dual mechanism of action peptide hybrids. PLoS One 8:e78154. ...
describes the structure and function of the GLP-1 receptor and the leading compound of existing small molecule drugs,also discusses the developing direction and application prospects of action mechanism of the GLP-1 receptor molecule structure,aiming to provide structure base for the treatment of T2DM...